Breye Therapeutics Raises €67.5M Series A Led by Novo Holdings

Breye Therapeutics Secures €67.5M Series A

Breye Therapeutics, a clinical-stage Danish biopharmaceutical company, has raised €67.5 million in Series A funding. The round was led by Novo Holdings and included participation from Catalyze Capital, EIFO, Sound Bioventures, Modi Ventures, Mission BioCapital, Innovestor, Ljungström Family Office, and Pappas Capital. The funding date is September 29, 2026.

What Breye Therapeutics Does

Based in Horsholm, near Copenhagen, Breye Therapeutics is developing oral therapeutics for the early treatment of retinal diseases. Its lead candidate, danegaptide, is a first-in-class oral small molecule designed to treat non-proliferative diabetic retinopathy (NPDR) by stabilizing the retinal vasculature. The company has completed Phase 1b testing, which showed early signs of clinical activity, and a randomized Phase 2 proof-of-concept trial is planned for 2027.

Beyond danegaptide, Breye's pipeline includes a P2X7 receptor antagonist for intermediate age-related macular degeneration and neuroprotective candidates in glaucoma.

The Series A Round

• Round type: Series A
• Amount raised: €67.5 million
• Lead investor: Novo Holdings
• Additional investors: Catalyze Capital, EIFO, Sound Bioventures, Modi Ventures, Mission BioCapital, Innovestor, Ljungström Family Office, Pappas Capital
• Funding date: September 29, 2026

The Series A brings together a syndicate of life science investors led by Novo Holdings, a major player in the biopharmaceutical sector. The participation of EIFO, Denmark's export and investment fund, alongside specialized venture firms, underscores confidence in Breye's approach to retinal disease.

Why This Matters for Acquirers

Breye Therapeutics operates in the ophthalmology space, where oral therapies for retinal diseases could offer a significant advantage over existing injectable treatments. The company's lead asset, danegaptide, targets NPDR, a condition that affects a large patient population and currently has limited early-treatment options. With Phase 1b complete and a Phase 2 trial planned for 2027, Breye is positioned to generate clinical data that could drive partnership or acquisition interest.

The broader pipeline, including a P2X7 receptor antagonist for intermediate AMD and neuroprotective candidates for glaucoma, provides multiple shots on goal. For acquirers looking to build a retinal disease franchise, Breye offers a clinical-stage asset with a differentiated mechanism and an oral route of administration.

Competitive Landscape

Retinal diseases such as diabetic retinopathy and age-related macular degeneration are major causes of vision loss worldwide. Current treatments often rely on intravitreal injections, which can be burdensome for patients. An oral small molecule like danegaptide could simplify treatment and potentially address earlier stages of disease. Breye's focus on stabilizing the retinal vasculature differentiates it from anti-VEGF therapies that primarily target later-stage disease.

Use of Funds

The company has not disclosed specific allocation of the proceeds, but the planned Phase 2 proof-of-concept trial for danegaptide in 2027 suggests a significant portion will fund clinical development. Additional resources may support the advancement of the P2X7 program and neuroprotective candidates.

Outlook

With a strong investor syndicate and a clear clinical milestone ahead, Breye Therapeutics is a company to watch in the retinal disease space. The Series A provides capital to execute on its Phase 2 trial and potentially expand its pipeline. For strategic acquirers and investors, Breye represents an opportunity to engage with a clinical-stage biotech addressing unmet needs in ophthalmology.